Petr Starostik, MD

PrintE-mail
Clinical Chief of Molecular Diagnostics
Associate Professor
Department of Pathology & Laboratory Medicine
Roswell Park Cancer Institute
Associate Professor of Pathology & Anatomical Sciences
School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise: 
Molecular Oncology

Research

Research Interests: 
Genetic aberrations in the development of malignancies

Background Information

Education and Training: 
MD - Vienna University School of Medicine, Vienna, Austria
Residency: 
Washington University School of Medicine, St. Louis, MO
Board Certification: 
Clinical Pathology, American Board of Pathology
Hematology, American Board of Pathology
Molecular Genetic Pathology, American Board of Pathology
Fellowships: 
MD Anderson Cancer Center, University of Texas, Houston, TX

Publications

Publications: 
  • , Nowak NJ, Wetzler M, Ford LA, Starostik P, Mashtare T, Gold D, Sait SNJ, Wang ES, Deeb G. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. Cancer genetics and cytogenetics 2010; 202(2):101-107
  • Battiwalla M , Hepgur M , Pan D , McCarthy PL , Ahluwalia MS , Camacho SH , Starostik P , Wallace PK. Multiparameter flow cytometry for the diagnosis and monitoring of small GPI-deficient cellular populations. Cytometry. Part B, Clinical cytometry 2010; 78(5):348-356
  • Malik DA , Starostik P , Deeb G , Risch N, Barcos M , Merzianu M. Comparative assessment of zinc-based fixatives in hematopathology practice. American journal of clinical pathology 2010; 134(4):58
  • Sher DA, Todd H, Webb-Martin T, Hocker K, Monroe TJ, Georgiou G, Taylor S, Fan H, Vaeyens F, Muniz-Fernandez A, Zhang H, Huang Y, Fuster O, Lambin S, Fletcher L, Watt C, Cai L, Webb CR, Starostik P, Vandenberghe P, Boeckx N, Winstall E, Romeo E, McNeil BK, Schrijver I, Wong CLP, Radich JP, Wei Q, Miller JE, Zamora L, Abbal C, Denys B, Callens C, Bakkus M, DeSchouwer PJ, Lint PV, Maes B, Colomer D, Pieters K, Shaw JH. Results of an international study of quantitative BCR/ABL assays using defined RNA samples. Blood 2010; 116(21):2742
  • Starostik P, Azrak S, Liang P, Wilding GE, Ademuyiwa FO, Khoury T. HER2 testing in breast cancer by universally primed quantitative multiplex PCR short fluorescent fragments (upQMPSF). Journal of clinical oncology 2010; 28(15 Suppl.):e11049
  • Block AW, Thompson JE, Wang ES, Starostik P, Deeb G, Sait SN, Ford L, Wilding GE, Groman AE, Wetzler M. The role of FLT3 in sole trisomy 8 acute myeloid leukemia. Journal of clinical oncology 2010; 28(15 Suppl.):6562
  • Iyer RV, Fakih M, Ma W, Tucker C, Levea C, Starostik P, Litwin A, Tan W, Khushalani NI, Adjei AA. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G) : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract# 258
  • Mhawech-Fauceglia P, Chan A, Keitz B, Lele S, Cheney RT, Starostik P. Microsatellite instability in large cell neuroendocrine carcinoma of the female genital tract. Histopathology 2009; 55(5):621-625
  • Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, Starostik P, Wetzler M, Mashtare T, Wang ES. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leukemia research 2011; 35(5):579-584
  • Czuczman MS, Deans J, Starostik P, Knight J, Kaur H, Binder A, Kotowski A, Gowda A, Olejniczak S, Hernandez-Ilizaliturri FJ. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clinical cancer research 2008; 14(5):1561-1570
  • Fakih MG, Ross ME, Starostik P. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities. Clinical colorectal cancer 2007; 6(8):583-587
  • Abdelhalim A, Barcos M, Block AW, Sait SN, Starostik P, Wetzler M, Wang ES. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. Leukemia and lymphoma 2007; 48(5):1053-1056
  • Khoury T, Mojica W, Hicks D, Starostik P, Ademuyiwa F, Janarthanan B, Cheney RT. ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. Modern pathology 2011; 24(8):1055-1059
  • Ailawadhi S, Hernandez-Ilizaliturri FJ, Miner L, Bernstein ZP, Chanan-Khan A, Miller KC, Mohr A, Starostik P, Czuczman MS, Padmanabhan S. Differences in BCL-2 protein and t(14;18) in patients with primary Rituximab/Chemotherapy refractory diffuse large B-Cell lymphoma (DLBCL). Blood 2007; 110(11 Part 2):177B (Abstract #4433)
  • Azrak S, Ping L, Starostik P, Wilding G, Khoury T. Universally-Primed Quantitative Multiplex PCR Short Fluorescent Fragments (upQMPSF): A New Detection Method for HER2 Amplification in Breast Cancer. Laboratory investigation 2009; 89(Suppl. 1):28A (Abstract #113)
  • Higgs DE, Bogner PN, Hicks DG, Starostik P, Wilding GE, Mashtare TL, Merzianu M. Oligo- and polyclonal B cell response to lung carcinoma is common. Laboratory investigation 2007; 87(Suppl. 1):1486
  • McInnis I, Hahn T, Ioane A, Larnson A, Lal D, Ford LA, Sait SNJ, Starostik P, Deeb G, Wetzler M, Mashtare T, Wang ES. Diverse Roles of Hepatocyte Growth Factor (HGF) in Normal Karyotype Acute Myeloid Leukemia (AML). Blood 2009; 114(22):1208
  • Smonskey M, Starostik P, Deeb G, Demock K, Vargas R, Lal D, Sait SN, Wetzler M, Wang ES. Association of IDH1 mutations in normal karyotype acute myeloid leukemia samples with higher HIF-1{alpha} and VEGF-A expression : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6530
  • Smonskey MT, Block AW, Deeb G, Chanan-Khan AA, Bernstein ZP, Miller KC, Wallace PK, Starostik P. Monoallelic and Biallelic Deletions of 13q14.3 in Chronic Lymphocytic Leukemia: FISH vs miRNA RT-qPCR Detection. American journal of clinical pathology 2012; 137(4):641-646
  • Ailawadhi S, Mashtare TL, Coignet MV, DePaolo DM, Miller KC, Padmanabhan S, Wilding G, Starostik P, Chanan-Khan AA. bcl-2 translocation [t(14;18) (q32;q21)] does not correlate with poor clinical outcome in multiple myeloma patients treated with bortezomib. Blood 2007; 110(11 Part 1):Abstract #1498